Ticker
LLY

Price
586.46
Stock movement up
+13.23 (2.31%)
Company name
Eli Lilly and Company
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Markedsverdi
558.51B
Ent verdi
595.16B
Pris/omsetning
19.57
Pris/bok
51.83
Utbytte avkastning
0.77%
Utbytte vekst
13.51%
Vekst år
7
FCF-utbetaling
63.44%
Etterfølgende P/E
89.44
Fremtidig P/E
50.08
PEG
6.79
EPS-vekst
17.40%
1 års avkastning
88.21%
3 års avkastning
57.22%
5 års avkastning
40.87%
10 års avkastning
27.37%
Sist oppdatert: 2023-09-08
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
15. september 2023

iO Charts is a Seeking Alpha partner

Eli Lilly's stock benefits from strong results and Novo Nordisk's successful weight loss drug, Wegovy. Read here to know why we recommend a buy on LLY stock.
14. september 2023

iO Charts is a Seeking Alpha partner

UTBYTTE

Utbytte – 5 år

Loading...
Data om utbytte
Utbytte per aksje4.52
Utbytte0.77%
UtbetalingsfrekvensKvartalsvis
Maksimal avkastning2.66%
Gjennomsnittlig avkastning1.73%
Minimum avkastning0.77%
Rabatt til gjennomsnittlig avkastning-123.89%
Oppsidepotensial-55.33%
Avkastning som % av maks avkastning29.00%

Avkastningsfordeling (invers persentil) – 5 år

Loading...
Avkastning distribusjonsdata
Utbytte0.77%
Nåværende avkastningsfordeling99.92%
Avkastning ved 100% (Min.)0.77%
Avkastning ved 90 %1.17%
Avkastning ved 80 %1.27%
Avkastning ved 50 % (median)1.77%
Avkastning ved 20 %2.20%
Avkastning ved 10 %2.30%
Avkastning ved 0 % (maks)2.66%

Utbytte per aksje

Loading...
Utbytte per aksje-data
År med vekst7 years
CCC-statusDividend Challenger
Utbytte per aksje4.52
UtbetalingsfrekvensKvartalsvis
Ex-div dato14 Aug 2023
EPS (TTM)6.57
EPS (1 år fremover)11.71
EPS-vekst (5 år)17.40%
EPS-vekst (5 år fremover)13.18%

Utbyttevekst

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Data om vekst i utbytte
LLYS&P500
DGR MR15.31%8.78%
DGR TTM15.30%8.57%
DGR 3 år14.96%4.00%
DGR 5 år13.51%5.65%
DGR 10 år7.18%7.37%
DGR 15 år5.73%5.83%
Tid siden forrige endring annonsert283 days
EPS-vekst (5 år)17.40%
EPS-vekst (5 år fremover)13.18%

Utbetalingsforhold

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Utbetalingsforhold-data
EPS-dekningFCF-dekning
TTM56.62%63.44%
Gjennomsnitt--
Fremover38.60%-
Eli Lilly and Company (NYSE:NYSE:LLY) Morgan Stanley 21st Annual Global Healthcare Conference 2023 Call September 11, 2023 2:55 PM ETCompany ParticipantsDan Skovronsky - Chief Scientific...
11. september 2023

iO Charts is a Seeking Alpha partner

Eli Lilly's stock is hitting new all-time highs as earnings continue to grow at a rapid rate. Read more about LLY stock here.
11. september 2023

iO Charts is a Seeking Alpha partner

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E89.44
Pris til OCF78.84
Pris til FCF100.21
Pris til EBITDA66.23
EV i forhold til EBITDA70.57

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning19.57
Pris til bok51.83
EV i forhold til salg20.85
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
10. september 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
8. september 2023

iO Charts is a Seeking Alpha partner

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall952.35M
EPS (TTM)6.57
FCF per aksje (TTM)5.87

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)28.54B
Bruttofortjeneste (TTM)21.91B
Driftsinntekter (TTM)8.11B
Netto inntekt (TTM)6.24B
EPS (TTM)6.57
EPS (1 år fremover)11.71

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)76.77%
Driftsmargin (TTM)28.43%
Fortjenestemargin (TTM)21.88%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter2.07B
Netto fordringer8.56B
Samlede omløpsmidler18.03B
Goodwill4.07B
Immaterielle eiendeler7.21B
Eiendom, anlegg og utstyr0.00
Sum eiendeler49.49B
Leverandørgjeld1.93B
Kortsiktig/nåværende langsiktig gjeld16.24B
Sum kortsiktig gjeld17.14B
Sum gjeld38.71B
Aksjonærenes egenkapital10.78B
Netto varige driftsmidler-629.80M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)7.08B
Kapitalutgifter (TTM)2.00B
Fri kontantstrøm (TTM)5.57B
Utbetalt utbytte (TTM)3.54B

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning57.95%
Avkastning på eiendeler12.62%
Avkastning på investert kapital23.12%
Kontantavkastning på investert kapital20.63%
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
7. september 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
2. september 2023

iO Charts is a Seeking Alpha partner

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning572.33
Daglig høy587.52
Daglig lav571.60
Daglig volum3.65M
Tidenes høyeste586.46
1 år analytikerestimat380.75
Beta0.35
EPS (TTM)6.57
Utbytte per aksje4.52
Ex-div dato14 Aug 2023
Neste dato for resultatpresentasjon2 Nov 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
LLYS&P500
Nåværende prisfall fra toppnotering-1.07%-5.59%
Høyeste prisfall-74.70%-56.47%
Dato for høyeste fall5 Mar 20099 Mar 2009
Gj.snittlig fall fra topp-30.92%-11.49%
Gj.snittlig tid til ny topp31 days13 days
Maks tid til ny topp4567 days1805 days
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
31. august 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
29. august 2023

iO Charts is a Seeking Alpha partner

SELSKAPSOPPLYSNINGER
LLY (Eli Lilly and Company) company logo
Markedsverdi
558.51B
Markedsverdi kategori
Large-cap
Beskrivelse
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Ansatte
39000
SEC-innsendelser
Adm. direktør
David Ricks
Land
USA
By
Indianapolis
Aksjetype
Common stock
CCC-status
Dividend Challenger
Utbyttefrekvens
Kvartalsvis
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
27. august 2023

iO Charts is a Seeking Alpha partner

Eli Lilly (LLY) and Novo Nordisk's (NVO) current valuations are not sustainable and there exist numerous adverse factors. Learn what are those adverse factors.
24. august 2023

iO Charts is a Seeking Alpha partner

FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Seeking AlphaPressemeldinger
Eli Lilly is in an epic bubble, pricing in all growth through 2036 and trading at almost 60X forward earnings. Find out another dividend aristocrat pick to buy.
23. august 2023
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
22. august 2023
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
21. august 2023
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
15. august 2023
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
14. august 2023
Eli Lilly's strong Q2 performance led to a significant price rally, but concerns arise over its valuation amidst pipeline results. Learn more on LLY stock here.
14. august 2023
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
14. august 2023
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
9. august 2023
Eli Lilly and Company reported Q2 results exceeding expectations and raised 2023 revenue guidance. Click here to read why LLY stock is a Strong Buy.
8. august 2023
Eli Lilly and Co (NYSE:NYSE:LLY) Q2 2023 Earnings Conference Call August 8, 2023 9:00 AM ETCompany ParticipantsJoe Fletcher - VP, IRDavid Ricks - Chairman, CEO & PresidentAnat Ashkenazi...
8. august 2023
iO Charts is a Seeking Alpha partnerNeste side